This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

AM-111 in the Treatment of Acute Inner Ear Hearing Loss (HEALOS)

This study is currently recruiting participants.
See Contacts and Locations
Verified January 2017 by Auris Medical, Inc. ( Auris Medical AG )
Sponsor:
Information provided by (Responsible Party):
Auris Medical, Inc. ( Auris Medical AG )
ClinicalTrials.gov Identifier:
NCT02561091
First received: September 23, 2015
Last updated: January 18, 2017
Last verified: January 2017
  Purpose
The purpose of this research study is to test the effectiveness and safety of the study drug, AM-111. AM-111 is tested for the treatment of sudden sensorineural hearing loss where the cause is unknown.

Condition Intervention Phase
Hearing Loss Other: Placebo Drug: AM-111 0.4 mg/ml Drug: AM-111 0.8 mg/ml Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss

Resource links provided by NLM:


Further study details as provided by Auris Medical, Inc. ( Auris Medical AG ):

Primary Outcome Measures:
  • Pure tone average (PTA; average of the hearing threshold of three contiguous most affected hearing frequencies in dB) [ Time Frame: Day 28 ]
    Assessment with pure tone audiometry/ Measurement at 8 frequencies/ Final outcome is the absolute improvement in PTA from D0 to D28


Estimated Enrollment: 255
Study Start Date: November 2015
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo gel for intratympanic use
Other: Placebo
Experimental: AM-111 0.4 mg/ml
AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
Drug: AM-111 0.4 mg/ml
Experimental: AM-111 0.8 mg/ml
AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
Drug: AM-111 0.8 mg/ml

Detailed Description:
This phase III study is assessing the drug's safety and is aiming to demonstrate efficacy of intratympanic AM-111 injections in the treatment of severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL). The active pharmaceutical ingredient of AM-111 is the JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino acids, which acts as a c-Jun N-terminal kinase (JNK) ligand.
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Unilateral ISSNHL with onset within 72 hours prior to study treatment;
  2. Mean hearing threshold of equal to or worse than (≥) 60 dB averaged across the 3 most affected contiguous air conduction audiometric pure tone frequencies ("pure tone average", PTA);*
  3. Mean hearing loss of equal to or worse than (≥) 40 dB averaged across the air conducted PTA frequencies compared with the unaffected contralateral ear or reference values from a pre-existing audiogram or ISO 7029;2000 norm values in case of asymmetric hearing prior to the ISSNHL incident;
  4. Age ≥ 18 and ≤ 65 years on the day of screening;

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  1. Bilateral ISSNHL;
  2. Acute hearing loss from noise trauma, barotrauma or head trauma;
  3. History of autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops or Menière's disease in the affected ear;
  4. History of chronic inflammatory or suppurative ear disease or cholesteatoma in the affected ear;
  5. History of acoustic neuroma or other retrocochlear damage in the affected ear;
  6. History of otosclerosis in the affected ear;
  7. Suspected perilymph fistula or membrane rupture in the affected ear;
  8. Congenital hearing loss;
  9. History of ISSNHL in the past 2 years;
  10. Otitis media or otitis externa that is ongoing or ended within 7 days prior to study treatment;

Other protocol-defined exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02561091

Contacts
Contact: Auris Medical +41 61 201 13 50

Locations
Bulgaria
Please check link to study webpage below for more study sites Recruiting
Sofia, Bulgaria
Sponsors and Collaborators
Auris Medical AG
  More Information

Additional Information:
Responsible Party: Auris Medical AG
ClinicalTrials.gov Identifier: NCT02561091     History of Changes
Other Study ID Numbers: AM-111-CL-13-01
Study First Received: September 23, 2015
Last Updated: January 18, 2017

Keywords provided by Auris Medical, Inc. ( Auris Medical AG ):
Deafness
Hearing Loss, Sensorineural
Ear Diseases
Hearing Disorders
Otorhinolaryngologic Diseases
Sensation Disorders
Signs and Symptoms
Hearing and Speech impairment
Hearing Loss, Unilateral

Additional relevant MeSH terms:
Hearing Loss
Deafness
Hearing Loss, Sensorineural
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on August 18, 2017